Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

What this Trial Is About

This research focuses on various hematological malignancies as classified by the WHO 2016 guidelines, including acute and chronic leukemias, myeloproliferative and lymphoproliferative disorders, and myelodysplastic syndromes. It aims to study these blood cancers by analyzing bone marrow, peripheral blood, lymph node, or tissue samples collected both retrospectively and prospectively at the University Hospital of Parma. The study evaluates molecular and genetic characteristics to better understand these diseases and identify potential new treatments. Participants include patients with hematological malignancies who are either treatment-free or have relapsed or refractory conditions. Samples are collected from diagnostic procedures such as bone marrow aspirates, biopsies, and peripheral blood draws. Advanced genetic, molecular, and omics technologies like Nanostring, next-generation sequencing, and single-cell analysis are used to study these samples. This process includes examining molecular biomarkers and correlating anti-cancer responses with diagnostic and molecular features. Participants will undergo sample collection from existing or new diagnostic evaluations. Researchers will analyze these samples to assess the activity of bio-active compounds and investigational molecules at baseline. The study also monitors molecular biomarkers and diagnostic features to explore novel target therapies. Participation involves informed consent and may include follow-up visits. The goal is to improve understanding of hematological malignancies through comprehensive molecular profiling, with no intervention or treatment administered as part of the study.

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)